

# Andreas D Meid

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8874227/publications.pdf>

Version: 2024-02-01

50  
papers

747  
citations

567144

15  
h-index

552653

26  
g-index

52  
all docs

52  
docs citations

52  
times ranked

1312  
citing authors

#	ARTICLE	IF	CITATIONS
1	Is Polypharmacy Associated with Frailty in Older People? Results From the <sc>ESTHER</sc> Cohort Study. <i>Journal of the American Geriatrics Society</i> , 2017, 65, e27-e32.	1.3	154
2	Health Service Use, Costs, and Adverse Events Associated with Potentially Inappropriate Medication in Old Age in Germany: Retrospective Matched Cohort Study. <i>Drugs and Aging</i> , 2017, 34, 289-301.	1.3	48
3	Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. <i>Therapeutic Advances in Psychopharmacology</i> , 2017, 7, 251-264.	1.2	43
4	Impact of an electronic clinical decision support system on workflow in antenatal care: the QUALMAT eCDSS in rural health care facilities in Ghana and Tanzania. <i>Global Health Action</i> , 2015, 8, 25756.	0.7	40
5	The impact of pharmaceutical care interventions for medication underuse in older people: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 768-776.	1.1	38
6	Dried-Blood-Spot Technique to Monitor Direct Oral Anticoagulants: Clinical Validation of a UPLC-MS/MS-Based Assay. <i>Analytical Chemistry</i> , 2018, 90, 9395-9402.	3.2	33
7	Medication Underuse in Aging Outpatients with Cardiovascular Disease: Prevalence, Determinants, and Outcomes in a Prospective Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0136339.	1.1	31
8	Changes in prescribed medicines in older patients with multimorbidity and polypharmacy in general practice. <i>BMC Family Practice</i> , 2018, 19, 131.	2.9	30
9	Investigating the Additive Interaction of QT-Prolonging Drugs in Older People Using Claims Data. <i>Drug Safety</i> , 2017, 40, 133-144.	1.4	29
10	Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia. <i>Clinical Epigenetics</i> , 2019, 11, 188.	1.8	27
11	Osteoporotic hip fracture prediction from risk factors available in administrative claims data – A machine learning approach. <i>PLoS ONE</i> , 2020, 15, e0232969.	1.1	25
12	<i>SLCO1B1</i> Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine. <i>OMICS A Journal of Integrative Biology</i> , 2016, 20, 538-545.	1.0	22
13	The impact of potentially inappropriate medication on the development of health care costs and its moderation by the number of prescribed substances. Results of a retrospective matched cohort study. <i>PLoS ONE</i> , 2018, 13, e0198004.	1.1	20
14	Longitudinal evaluation of medication underuse in older outpatients and its association with quality of life. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 877-885.	0.8	19
15	Association of preventable adverse drug events with inpatients' length of stay-A propensity-matched cohort study. <i>International Journal of Clinical Practice</i> , 2017, 71, e12990.	0.8	19
16	Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2903-2913.	1.1	17
17	Comparative evaluation of methods approximating drug prescription durations in claims data: modeling, simulation, and application to real data. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1434-1442.	0.9	14
18	Role of NR1I2 (pregnane X receptor) polymorphisms in head and neck squamous cell carcinoma. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2015, 388, 1141-1150.	1.4	12

#	ARTICLE	IF	CITATIONS
19	Prediction of Drug-Related Risks Using Clinical Context Information in Longitudinal Claims Data. <i>Value in Health</i> , 2018, 21, 1390-1398.	0.1	8
20	The Role of Adherence Thresholds for Development and Performance Aspects of a Prediction Model for Direct Oral Anticoagulation Adherence. <i>Frontiers in Pharmacology</i> , 2019, 10, 113.	1.6	8
21	Disease-dependent variations in the timing and causes of readmissions in Germany: A claims data analysis for six different conditions. <i>PLoS ONE</i> , 2021, 16, e0250298.	1.1	8
22	Pill-count and the arithmetic of risk: Evidence that polypharmacy is a health status marker rather than a predictive surrogate for the risk of adverse drug events. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2018, 56, 572-576.	0.3	8
23	Low Exposure to Direct Oral Anticoagulants Is Associated with Ischemic Stroke and Its Severity. <i>Journal of Stroke</i> , 2022, 24, 88-97.	1.4	8
24	Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 433-439.	1.1	7
25	A prognostic model predicted deterioration in health-related quality of life in older patients with multimorbidity and polypharmacy. <i>Journal of Clinical Epidemiology</i> , 2021, 130, 1-12.	2.4	7
26	Age-Dependent Impact of Medication Underuse and Strategies for Improvement. <i>Gerontology</i> , 2016, 62, 491-499.	1.4	6
27	New Insights Into the Pharmacokinetics of Vancomycin After Oral and Intravenous Administration: An Investigation in Beagle Dogs. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 2090-2094.	1.6	6
28	The impact of a computerized physician order entry system implementation on 20 different criteria of medication documentation – a before-and-after study. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 279.	1.5	6
29	Can Machine Learning from Real-World Data Support Drug Treatment Decisions? A Prediction Modeling Case for Direct Oral Anticoagulants. <i>Medical Decision Making</i> , 2021, , 0272989X2110646.	1.2	6
30	How can we define and analyse drug exposure more precisely to improve the prediction of hospitalizations in longitudinal (claims) data?. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 373-380.	0.8	5
31	<p>Using the Causal Inference Framework to Support Individualized Drug Treatment Decisions Based on Observational Healthcare Data</p>. <i>Clinical Epidemiology</i> , 2020, Volume 12, 1223-1234.	1.5	5
32	A framework to build similarity-based cohorts for personalized treatment advice – a standardized, but flexible workflow with the R package SimBaCo. <i>PLoS ONE</i> , 2020, 15, e0233686.	1.1	5
33	Are Anticholinergic Symptoms a Risk Factor for Falls in Older General Practice Patients With Polypharmacy? Study Protocol for the Development and Validation of a Prognostic Model. <i>Frontiers in Pharmacology</i> , 2020, 11, 577747.	1.6	4
34	Comparison of Five Lists to Identify Potentially Inappropriate Use of Non-Steroidal Anti-Inflammatory Drugs in Older Adults. <i>Pain Medicine</i> , 2021, 22, 1962-1969.	0.9	4
35	Estimated Thresholds of Minimum Necessary Adherence for Effective Treatment with Direct Oral Anticoagulants – A Retrospective Cohort Study in Health Insurance Claims Data. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 2209-2220.	0.8	4
36	Pain severity and analgesics use in the community-dwelling older population: a drug utilization study from Germany. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1695-1707.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Reporter cell assay-based functional quantification of TNF- $\alpha$ -antagonists in serum – a proof-of-principle study for adalimumab. <i>Analytical Biochemistry</i> , 2020, 596, 113646.	1.1	3
38	Predicting negative health outcomes in older general practice patients with chronic illness: Rationale and development of the PROPERmed harmonized individual participant data database. <i>Mechanisms of Ageing and Development</i> , 2021, 194, 111436.	2.2	3
39	Machine learning for tumor growth inhibition: Interpretable predictive models for transparency and reproducibility. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 257-261.	1.3	3
40	Refining estimates of prescription durations by using observed covariates in pharmacoepidemiologic databases: Necessary refinements to stimulate alternative approaches. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1135-1137.	0.9	2
41	Renal Safety of Hydroxyethyl starch 130/0.42 After Cardiac Surgery: A Retrospective Cohort Analysis. <i>Drug Safety</i> , 2021, 44, 1311-1321.	1.4	2
42	Prevalence and patient-rated relevance of complexity factors in medication regimens of community-dwelling patients with polypharmacy. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 1127-1136.	0.8	2
43	Real-world complexity of atrial fibrillation treatment with oral anticoagulants: design and interpretation of pharmacoepidemiological studies. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2321-2324.	1.1	1
44	Composite midazolam and 1 $\alpha$ -OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2020, 47, 527-542.	0.8	1
45	Predicting Hospital Readmissions from Health Insurance Claims Data: A Modeling Study Targeting Potentially Inappropriate Prescribing. <i>Methods of Information in Medicine</i> , 2022, 61, 055-060.	0.7	1
46	Teaching reproducible research for medical students and postgraduate pharmaceutical scientists. <i>BMC Research Notes</i> , 2021, 14, 445.	0.6	0
47	Title is missing!. , 2020, 15, e0232969.		0
48	Title is missing!. , 2020, 15, e0232969.		0
49	Title is missing!. , 2020, 15, e0232969.		0
50	Title is missing!. , 2020, 15, e0232969.		0